Is cardiac angiography dangerous?

Cardiac angiography is a common method of examining heart disease. It mainly involves using a very thin catheter, which is inserted into the aorta. Some contrast agents are then injected to achieve blood flow through x-rays, which are then displayed on a monitor to observe the shape of the blood vessels and heart. However, because it needs to be inserted into the aorta, it is somewhat dangerous, and there are also certain side effects from the drugs.

side effect

1. Orange tree expectorant can reduce the side effects of cardiac angiography

2. Research results show that this drug can reduce the incidence of renal failure in patients by 60%. The hospital conducted a clinical study involving 200 coronary cardiovascular patients. The 100 patients in the treatment group received 600 mg of orange tree expectorant orally one day before the angiography examination and once in the morning and evening on the day of the examination. As a result, only 4 people developed renal failure, while 12 people in the control group of 100 people who did not take Orange Tree Expectorant developed renal failure.

Kidney protection effect

1. Acetylcysteine ​​has a kidney-protecting effect during cardiac angiography

2. The antioxidant acetylcysteine ​​may prevent renal dysfunction in patients with renal insufficiency undergoing coronary angiography.

3. The renal protective effect of acetylcysteine ​​is similar in all patient subgroups, and the side effects are minimal. It had a protective effect in patients undergoing diagnostic and/or interventional coronary angiography, with similar changes in serum urea and creatinine concentrations, suggesting that "changes in glomerular filtration underlie the protective effect of acetylcysteine."

4.200 patients were randomized to a prospective, double-blind trial; 102 participants were assigned to take 600 mg of acetylcysteine ​​orally twice daily on the day before and on the day of angiography. The remaining 98 people received a placebo. The average age of the patients was 68 years, and their renal insufficiency was stable and moderate, that is, the creatinine clearance was less than 60 ml/min. All patients underwent coronary angiography with a low-osmotic contrast agent. The primary outcome measures included an increase of 25% or more in serum creatinine levels within 48 hours after dosing, creatinine clearance, and change in serum creatinine.